Substantial immune suppression required in gene therapy for  muscular dystrophy?
Herzog
Roland W
RW
Department of Pediatrics, University of Florida, Gainesville, FL, USA. rherzog@ufl.edu
Arruda
Valder R
VR
D000256:Adenoviridae / Q000235:genetics / Q000276:immunology; D000818:Animals; D004195:Disease Models, Animal; D004285:Dogs; D018014:Gene Transfer Techniques / Q000009:adverse effects / Q000592:standards; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods* / Q000592:standards; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods / Q000592:standards*; D051379:Mice; D018482:Muscle, Skeletal / Q000276:immunology* / Q000378:metabolism / Q000503:physiopathology; D009137:Muscular Dystrophy, Animal / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D019076:Transgenes / Q000235:genetics / Q000276:immunology